06448277 is referenced by 24 patents and cites 12 patents.

Described are compounds of formula (I), wherein W is O or S; X is NR

8

; Y is CR

9

R

10

—(CH

2

)n wherein R

9

and R

10

are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is S0

2

; R

1

is aryl; R

2

is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R

2

cannot represent 2-phthalimidyl, and in case of Y=SO

2

cannot represent 2,1,3-benzothiadiazol-4-yl; any of R

3

, R

4

, R

5

and R

6

, independently of the other, is H or a substituent other than hydrogen; and R

7

and R

8

, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

Title
VEGF receptor tyrosine kinase inhibitors
Application Number
9/850434
Publication Number
6448277 (B2)
Application Date
May 7, 2001
Publication Date
September 10, 2002
Inventor
Karl Heinz Thierauch
Berlin
US
Martin Haberey
Berlin
US
Andreas Menrad
Oranienburg
US
Dieter Seidelmann
Berlin
US
Martin Krüger
Berlin
US
Andreas Huth
Berlin
US
Jürgen Mestan
Denzlingen
US
Francesco Hofmann
Bottmingen
US
Stefano Ferrari
Muttenz
US
Jeanette Marjorie Wood
Biel-Benken
US
Paul William Manley
Arlesheim
US
Pascal Furet
Thann
US
Guido Bold
Gipf-Oberfrick
US
Karl Heinz Altmann
Reinach
US
Agent
George R Dohmann
US
Assignee
Schering Aktiengesellschaft
US
Novartis
US
IPC
A61K 31/166
View Original Source